Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Third Quarter 2016 Financial Results

Genmab will report its Third Quarter 2016 financial results after market close on November 2. An investor conference call to discuss the results will be held at 6:00 PM CET / 1:00 PM EDT on November 2. To join the call by phone, dial one of the following numbers and ask for the Genmab conference call: +45 3271 1660 in Denmark, +44 20 3427 0503 in the UK or +1 212 444 0895 in the US. Click here to listen to the webcast. 

nov 102016 Capital Markets Day

Genmab will host a Capital Markets Day on November 10, 2016 at the Four Seasons Hotel in New York. The meeting will feature a variety of Genmab speakers who will provide updates on our business including the clinical and pre-clinical pipelines, proprietary next generation antibody technologies and R&D capabilities. Click here for more information and to register for the event. This meeting will be webcast live and details on how to join the webcast will be available on


Lab tourVirtual Lab Tour

Watch our new virtual lab tour to learn more about Genmab’s research and development capabilities and our proprietary DuoBody® and HexaBody® technologies.